46 Accurso, Anthony et al., Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab 5: 9, 2008.
47 Page, K. A. et al., Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest 121 (10): 4161 – 4169, 2011.
48 Nagao, K./Yanagita, T., Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res 61 (3): 208 – 212, 2010.
49 Dehghan, M. et al., Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet 390 (10107): 2050 – 2062, 2017.
50 Calder, P. C., Functional roles of fatty acids and their effects on human health. J Parenter Enteral Nutr 39 (1 Suppl.): 18S – 32S, 2015.
51 May, A. L. et al., Prevalence of cardiovascular disease risk factors among US adolescents, 1999 – 2008. Pediatrics 129 (6): 1035 – 1041, 2012.
52 Faghihnia, N. et al., Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men. Eur J Clin Nutr 66 (11): 1229 – 1233, 2012.
53 Chowdbury, R. et al., Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160 (6): 398 – 406, 2014.
54 Hyman, Iss Fett, werde schlank, S. 201.
55 Cordain, L. et al., Fatty acid analysis of wild ruminant tissues: evolutionary implications for reducing diet-related chronic disease. Eur J Clin Nutr 56 (3): 181 – 191, 2002.
56 American Heart Association, Monosaturated fat. Siehe http://heart.org/HEARTORG/GettingHealthy/NutritionCenter/HEalthyEating/Monounsaturated-Fats_UCM_301460_Article.jsp. Abgerufen August 2018.
57 University of Maryland Medical System, Omega-3 fatty acids. Siehe http://umm.edu/health/medical/altmed/supplment/omega-3-fattyacids. Abgerufen August 2018.
58 Pawlak, D. B. et al., Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet 364 (9436): 778 – 785, 2004.
59 Adam, Olaf, Diät und Rat bei Rheuma und Osteoporose: Rezepte gegen Entzündung und Schmerz. Weil der Stadt: Hädecke 2005. 397
60 https://www.bfr.bund.de/cm/343/fuer_die_anreicherung_von_lebensmitteln_mit_omega_3_fettsaeuren_empfiehlt_das_bfr_die_festsetzung_von_hoechstmengen.pdf. Abgerufen August 2018.
61 Triff, K. et al., Chemoprotective epigenetic mechanisms in a colorectal cancer model: modulation by n-3 PUFA in combination with fermentable fiber. Curr Pharmacol Rep 1 (1): 11 – 30, 2015.
62 Devi, K. P. et al., Molecular targets of omega-3 fatty acids for cancer therapy. Anticancer Agents Med Chem 15 (7): 888 – 895, 2015.
63 Witte, Theodore R./Hardman, W. Elaine, The effects of omega-3 polyunsaturated fatty acid consumption on mammary carcinogenesis. Lipids 50 (5): 437 – 446, 2015.
64 Lin, Pao-Hwa et al., Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med 13: 3, 2015.
65 https://www.dge.de/wissenschaft/weitere-publikationen/fachinformationen/trans-fettsäuren. Abgerufen September 2018.
66 US Food and Drug Administration, Trans fat at-a-glance. Siehe http://ww.fda.gov/Food/IngredientsPackingLabeling/LabelingNutrition/ucm079609.htm. Abgerufen Juli 2018.
67 Willett, Walter, Eat, Drink and Be Healthy: The Harvard Medical School Guide to Healthy Eating, New York: Free Press 2001.
68 Kavanagh, K. et al., Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring) 15 (7): 1675 – 1684, 2007.
69 Harvard School of Public Health, «Shining the spotlight on transfats». Siehe http://hsph.harvard.edu/nutritionsource/transfats. Abgerufen August 2018.
70 Ascherio, A. et al., Trans fatty acids and coronary heart disease. N Engl J Med 340 (25): 1994 – 1998, 1999.
71 Walling, Elizabeth, A Real Killer: Trans Fat Causes Colon Cancer. Natural News 2009, siehe https://www.naturalnews.com/025960_trans_fat_food_cancer.html. Abgerufen September 2018.
72 Chajès, V. et al., Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. Am J Epidemiol 167 (11): 1312 – 1320, 2008.
73 2015 Dietary Guidelines Advisory Committee, Scientific report of the 2015 Dietary Guidelines Advisory Committee. Siehe http://www.health.gov/dietaryguidelines/2015-scientific-report/. Abgerufen August 2018.
74 Ramsden, C. E. et al., N-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-ana398lysis of randomised controlled trials. Br J Nutr 104 (11): 1586 – 1600, 2010.
75 Simopoulos, A. P., Evolutionary aspects of diet, the omega-6/omega-3ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60 (9): 502 – 507, 2006.
76 Yancy, W. S. Jr et al., A low-carbohydrate, ketogenic diet versus a lowfat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern. Med 140 (10): 769 – 777, 2004.
77 Calder, P. C., The American Heart Association advisory on n-6 fatty acids: evidence based or biased evidence? Br J Nutr 104 (11): 1575 – 1576, 2010.
78 Hibbeln, Joseph R. et al., Increasing homicide rates and linoleic acid consumption among five Western countries, 1961 – 2000. Lipids 39: 1207 – 1213, 2004.
79 Fallon, Sally/Enig, Mary G., The great Con-ola. 2002. Siehe http://www.westonaprice.org/health-topics/the-great-con-ola/. Abgerufen August 2018.
80 Silbernagl, Stefan/Despopoulos, Agamemnon/Draghun, Andras (Hg.), Taschenatlas Physiologie. 9. Auflage, Stuttgart: Thieme 2018.
81 Weston A. Price Foundation, Know your fats introduction. 2009. Siehe http://www.westonaprice.org/Health-topics/know-your-fats-introduction/. Abgerufen September 2018.
82 Opara, E. C. et al., Effects of fatty acids on insulin release: role of chain length and degree of saturation. Am J Physiol 266: E 635 – 639, 1994.
83 Lane, N., Power, sex, suicide: Mitochondria and the meaning of life. New York: Oxford University Press 2006.
84 Kuklinski, Bodo/Schemionek, Anja, Mitochodrientherapie – die Alternative. 5. Auflage, Bielefeld: Aurum Verlag 2016.
85 Wer dieses Thema vertiefen möchte, dem empfehle ich mein Buch Schlank und gesund mit der Doc Fleck Methode, Hilden: BJV Verlag 2017.
86 Pomplun, D. et al., Reduced expression of mitochondrial frataxin in mice exacerbates diet-induced obesity. Proceedings of the National Academy of Sciences (USA) 104 (15): 6377 – 6381, 2007.
87 Cypess, A. M. et al., Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360 (15): 1509 – 1517, 2009; Saito, M. et al., High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58 (7): 1526 – 1531, 2009; Van Marken Lichtenbelt, W. D. et al., 399 Cold-activated brown adipose tissue in healthy men. N Engl J Med 360 (15): 1500 – 1508, 2009; Virtanen, K. A. et al., Functional brown adipose tissue in healthy adults. N Engl J Med 360 (15): 1518 – 1525, 2009.
88 Christen, William G. et al., Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol 129 (7): 921 – 929, 2011.
89 Georgiou, T./Prokopiou, E., The new era of omega-3 fatty acids supplementation: therapeutic effects on dry age-related macular degeneration. J Stem Cells 10 (3): 205 – 215, 2015.
90 Jelinek, G. A. et al., Association of fish consumption and Ω 3 supplementation with quality of life, disability and disease activity in an international cohort of people with multiple sclerosis. Int J Neurosci 123 (11): 792 – 800, 2013.
91 Nordvik, I. et al., Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 102 (3): 143 – 149, 2000.
92 Perera, H. et al., Combined ω3 and ω6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. J Child Neurol 27 (6): 747 – 753, 2012.
93 Bickel, H., Demenzsyndrom und Alzheimer Krankheit: Eine Schätzung des Krankenbestandes und der jährlichen Neuerkrankungen in Deutschland. Gesundheitswesen 62 (4): 211 – 218, 2000.
94 Riedel-Heller, S. G. et al., Recruitment procedures and their impact on the prevalence of dementia. Neuroepidemiology 19: 130 – 140, 2000.
95 Möller, T., Borne, C., Reiser, M. et al., Alzheimer Krankheit und vaskuläre Demenz Bd. 5, Springer Verlag Wien, 54 – 61, 2009.
96 Wancata, J. et al., Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18 (6): 306 – 313, 2003.
97 De la Monte, S. M., Insulin resistance and Alzheimer’s disease. BMB Reports 42 (8): 475 – 481, 2009.
98 Robers, R. O. et al., Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia. J Alzheimer’s Dis 32 (2): 329 – 39, 2012.
99 Henderson, Samuel T. et al., Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutrition&Metabolism 6: 31, 2006.
100 Mercola, Fat for fuel. 400
101 Wheless, J. W., History of the ketogenic diet. Epilepsias 49 Suppl. 8: 3 – 5, 2008.
102 Martin, K. et al., Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database of Systematic Reviews 2016, 2.
103 DeGiorgio, C. M. et al., Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study. J Neurol Neurosurg Psychiatry 86 (1): 65 – 70, 2015.
104 Reda, D. M. et al., Fish Oil Intake and Seizure Control in Children with Medically Resistant Epilepsy. N Am J Med Sci. 7 (7): 317 – 21, 2015.